Bio­Marin taps AI up­start Deep Ge­nomics for dis­cov­ery pact; Prax­is says it has a path to lift­ing clin­i­cal hold

Years af­ter dou­ble FDA/EMA re­jec­tions left Bio­Marin’s oligonu­cleotide for Duchenne mus­cu­lar dy­s­tro­phy lan­guish­ing on the shelf, the com­pa­ny is go­ing back to the draw­ing board …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER